BTIG analyst Justin Zelin initiated coverage of ImmunityBio (IBRX) with a Buy rating and $6 price target Lead product Anktiva is approved in BCG-unresponsive non-muscle invasive bladder cancer based on “compelling” complete response rates and durability, says the analyst, who sees the company’s partnership with Serum Institute of India for development of recombinant BCG as “a prudent approach to address the BCG shortage long-term.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- Largest borrow rate increases among liquid names
- Broadcom tops $1T market cap on AI enthusiasm: Morning Buzz
- Adobe outlook disappoints, Kroger announces $7.5B buyback: Morning Buzz
- Albertsons terminates Kroger deal, Macy’s reports Q3 beat: Morning Buzz
- ImmunityBio 33.333M share Spot Secondary priced at $3.00